Discounted Cash Flow
Acadia Pharmaceuticals Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $17.3m | $-271.4m | $-209.9m | -1565.9% | $-2.34 |
| 2017 | $124.9m (620.7%) | $-289.4m (-6.6%) | $-218.6m (-4.1%) | -231.7% (85.2%) | $-2.36 (-0.9%) |
| 2018 | $223.8m (79.2%) | $-245.2m (15.3%) | $-169.6m (22.4%) | -109.6% (52.7%) | $-1.94 (17.8%) |
| 2019 | $339.1m (51.5%) | $-235.3m (4.1%) | $-152.3m (10.2%) | -69.4% (36.7%) | $-1.60 (17.5%) |
| 2020 | $441.8m (30.3%) | $-281.6m (-19.7%) | $-143.8m (5.6%) | -63.7% (8.1%) | $-1.79 (-11.9%) |
| 2021 | $484.1m (9.6%) | $-167.9m (40.4%) | $-126.8m (11.8%) | -34.7% (45.6%) | $-1.05 (41.3%) |
| 2022 | $517.2m (6.8%) | $-216.0m (-28.7%) | $-114.0m (10.1%) | -41.8% (-20.4%) | $-1.34 (-27.6%) |
| 2023 | $726.4m (40.4%) | $-61.3m (71.6%) | $16.7m (114.6%) | -8.4% (79.8%) | $-0.37 (72.4%) |
| 2024 | $957.8m (31.8%) | $226.5m (469.5%) | $157.2m (844.0%) | 23.6% (380.2%) | $1.37 (470.3%) |
| 2025 | $1.1b (11.9%) | $391.0m (72.7%) | $105.1m (-33.1%) | 36.5% (54.3%) | $2.32 (69.3%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.